138 related articles for article (PubMed ID: 2127549)
1. Sodium nitroprusside modulates the fibrinolytic system in the rabbit.
Lidbury PS; Korbut R; Vane JR
Br J Pharmacol; 1990 Nov; 101(3):527-30. PubMed ID: 2127549
[TBL] [Abstract][Full Text] [Related]
2. Effect of organic nitrates on ex vivo platelet aggregation and fibrinolysis in man.
Wolfram G; Meyer U; Scheske U; Horn M; Drummer C; Spannagl M; Gerzer R
Eur J Med Res; 1996 Mar; 1(6):291-8. PubMed ID: 9367942
[TBL] [Abstract][Full Text] [Related]
3. The potential role of platelet PAl-1 in t-PA mediated clot lysis of platelet rich plasma.
Serizawa K; Urano T; Kozima Y; Takada Y; Takada A
Thromb Res; 1993 Aug; 71(4):289-300. PubMed ID: 8236158
[TBL] [Abstract][Full Text] [Related]
4. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA.
Urano T; Sumiyoshi K; Pietraszek MH; Takada Y; Takada A
Thromb Haemost; 1991 Oct; 66(4):474-8. PubMed ID: 1796399
[TBL] [Abstract][Full Text] [Related]
5. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat.
Reilly CF; Fujita T; Mayer EJ; Siegfried ME
Arterioscler Thromb; 1991; 11(5):1276-86. PubMed ID: 1911713
[TBL] [Abstract][Full Text] [Related]
6. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
Carr ME; Krishnamurti C; Alving BM
Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
[TBL] [Abstract][Full Text] [Related]
7. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
8. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
9. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
[TBL] [Abstract][Full Text] [Related]
10. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
Lucore CL; Fujii S; Sobel BE
Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
[TBL] [Abstract][Full Text] [Related]
11. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature.
Stein CM; Brown N; Vaughan DE; Lang CC; Wood AJ
J Am Coll Cardiol; 1998 Jul; 32(1):117-22. PubMed ID: 9669258
[TBL] [Abstract][Full Text] [Related]
12. Effects of recombinant plasminogen activator inhibitor type 1 on fibrinolysis in vitro and in vivo.
Knabb RM; Chiu AT; Reilly TM
Thromb Res; 1990 Jul; 59(2):309-17. PubMed ID: 2122539
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.
Torr-Brown SR; Sobel BE
Thromb Res; 1993 Dec; 72(5):413-21. PubMed ID: 8303684
[TBL] [Abstract][Full Text] [Related]
14. Fluctuations of euglobulin lysis time, tissue plasminogen activator, and free and total plasminogen activator inhibitor levels in plasma in daytime.
Takada A; Takada Y; Urano T; Sakakibara K; Rydzewski A
Thromb Res; 1990 Jan; 57(1):13-20. PubMed ID: 2105539
[TBL] [Abstract][Full Text] [Related]
15. Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease.
Rydzewski A; Sakata K; Kobayashi A; Yamazaki N; Urano T; Takada Y; Takada A
Haemostasis; 1990; 20(5):305-12. PubMed ID: 2127039
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time.
Wright JG; Cooper P; Astedt B; Lecander I; Wilde JT; Preston FE; Greaves M
Br J Haematol; 1988 Jun; 69(2):253-8. PubMed ID: 3134043
[TBL] [Abstract][Full Text] [Related]
17. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
[TBL] [Abstract][Full Text] [Related]
18. Time dependent release of tissue-type plasminogen activator and plasminogen activator inhibitor into the circulation of pigs during shock.
Siebeck M; Spannagl M; Hoffmann H; Schramm W; Fritz H
Blood Coagul Fibrinolysis; 1991 Jun; 2(3):459-64. PubMed ID: 1834237
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
Krishnamurti C; Young GD; Barr CF; Colleton CA; Alving BM
J Lab Clin Med; 1991 Dec; 118(6):523-30. PubMed ID: 1744501
[TBL] [Abstract][Full Text] [Related]
20. Relationships between serum lipids, serotonin, platelet aggregation and some fibrinolytic parameters in humans.
Malyszko J; Urano T; Knofler R; Ihara H; Takada Y; Takada A
Life Sci; 1994; 55(21):1619-23. PubMed ID: 7968236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
